Hannover Clinical Trial Center GmbH, Carl-Neuberg-Strasse. 1/k27, 30625 Hannover, Germany.
Exp Cell Res. 2013 Oct 15;319(17):2700-7. doi: 10.1016/j.yexcr.2013.06.015. Epub 2013 Jun 29.
Continuing efforts in development of non-invasive prenatal genetic tests have focused on the isolation of fetal nucleated red blood cells (NRBCs) from maternal blood for decades. Because no fetal cell-specific antibody has been described so far, the present study focused on the development of monoclonal antibodies (mAbs) to antigens that are expressed exclusively on fetal NRBCs.
Mice were immunized with fetal erythroid cell membranes and hybridomas screened for Abs using a multi-parameter fluorescence-activated cell sorting (FACS). Selected mAbs were evaluated by comparative FACS analysis involving Abs known to bind erythroid cell surface markers (CD71, CD36, CD34), antigen-i, galactose, or glycophorin-A (GPA). Specificity was further confirmed by extensive immunohistological and immunocytological analyses of NRBCs from umbilical cord blood and fetal and adult cells from liver, bone marrow, peripheral blood, and lymphoid tissues.
Screening of 690 hybridomas yielded three clones of which Abs from 4B8 and 4B9 clones demonstrated the desired specificity for a novel antigenic structure expressed on fetal erythroblast cell membranes. The antigenic structure identified is different from known surface markers (CD36, CD71, GPA, antigen-i, and galactose), and is not present on circulating adult erythroid cells, except for occasional detectability in adult bone marrow cells.
The new mAbs specifically bind the same or highly overlapping epitopes of a surface antigen that is almost exclusively expressed on fetal erythroid cells. The high specificity of the mAbs should facilitate development of simple methods for reliable isolation of fetal NRBCs and their use in non-invasive prenatal diagnosis of fetal genetic status.
几十年来,人们一直在努力开发非侵入性产前基因检测技术,专注于从母体血液中分离胎儿有核红细胞(NRBCs)。由于迄今为止尚未描述任何胎儿细胞特异性抗体,因此本研究集中于开发仅在胎儿 NRBCs 上表达的抗原的单克隆抗体(mAbs)。
用胎儿红细胞膜免疫小鼠,并用多参数荧光激活细胞分选(FACS)筛选杂交瘤以获得 Abs。通过涉及已知与红细胞表面标记物(CD71、CD36、CD34)、抗原-i、半乳糖或血型糖蛋白-A(GPA)结合的 Abs 的比较 FACS 分析来评估选定的 mAbs。通过对脐带血和胎儿及成人细胞(肝、骨髓、外周血和淋巴组织)中的 NRBC 进行广泛的免疫组织化学和免疫细胞化学分析进一步确认了特异性。
筛选了 690 个杂交瘤,得到了 3 个克隆,其中来自 4B8 和 4B9 克隆的 Abs 表现出对胎儿红系细胞膜上表达的新型抗原结构的所需特异性。鉴定出的抗原结构与已知的表面标记物(CD36、CD71、GPA、抗原-i 和半乳糖)不同,并且不存在于循环的成人红细胞中,除了在成人骨髓细胞中偶尔可检测到。
新的 mAbs 特异性地结合在胎儿红系细胞上几乎仅表达的表面抗原的相同或高度重叠的表位上。mAbs 的高特异性应有助于开发用于可靠分离胎儿 NRBCs 及其在非侵入性产前诊断胎儿遗传状态中的简单方法。